安罗替尼联合多西他赛用于酪氨酸激酶抑制剂联合含铂类化疗失败非小细胞肺癌患者的疗效
Efficacy of anlotinib combined with docetaxel in first-line treatment failure of patients with NSCLC
张春晓 1张群妹 2鲁广建3
作者信息
- 1. 新乡医学院第一附属医院呼吸重症监护室,新乡 453100
- 2. 新乡医学院第一附属医院输血科,新乡 453100
- 3. 新乡医学院第一附属医院检验科,新乡 453100
- 折叠
摘要
目的 探讨安罗替尼联合多西他赛应用于酪氨酸激酶抑制剂联合含铂类化疗失败NSCLC患者的疗效.方法 选取2021年6月—2022年5月新乡医学院第一附属医院予以酪氨酸激酶抑制剂联合含铂类化疗失败NSCLC患者83例为此次试验对象,采取随机数字表法将83例患者分为两组,给予对照组(41例)安罗替尼治疗,给予观察组(42例)安罗替尼及多西他赛联合治疗,数据比较:疗效、治疗前后VEGF、MMP9及不良反应.结果 较对照组总有效率(68.29%),观察组(88.10%)更高,P<0.05.观察组VEGF、MMP9水平为(82.34±11.45)pg·mL-1、(82.46±7.26)ng·mL-1,均优于对照组患者(114.67±11.57)pg·mL-1、(132.18±7.12)ng·mL-1,t=12.795、31.493,P<0.05.观察组与对照组不良反应发生率对比(23.81%vs.12.20%)差异无统计学意义(χ2=1.890,P>0.05).结论 安罗替尼联合多西他赛应用于酪氨酸激酶抑制剂联合含铂类化疗失败NSCLC患者能够提高治疗效果,降低血清VEGF、MMP9水平.
Abstract
Objective To explore the efficacy of anlotinib combined with docetaxel in patients with non-small cell lung cancer(NSCLC)having failure of chemotherapy of tyrosine kinase inhibitor combined with platinum.Methods A total of 83 patients with NSCLC who failed to receive tyrosine kinase inhibitor combined with platinum chemotherapy in our hospital from June 2021 to May 2022 were selected as the subjects in this study.The 83 patients were randomized into the control group(n=41)and observation group(n=42).The patients in the control group were treated with anlotinib and those in the observation one with the combination of allotinib and docetaxel.The efficacy,vascular endothelial growth factor(VEGF),matrix metalloproteinase 9(MMP9)before and after treatment and adverse reactions were compared between the 2 groups.Results The total effective rate was significantly lower in the control group in the observation one(68.29%vs 88.10%,P<0.05).VEGF and MMP9 levels in the observation group were significantly improved as compared with the control[(82.34±11.45) pg·mL-1 vs(114.67±11.57) pg·mL-1,(82.46±7.26) ng·mL-1 vs(132.18±7.12) ng·mL-1,t=12.795,31.493,P<0.05].There was no statistical difference in occurrence of adverse reactions between the 2 groups(23.81%vs 12.20%)(χ2=1.890,P>0.05).Conclusion Anlotinib combined with docetaxel can improve the therapeutic effect and reduce serum VEGF and MMP9 levels in NSCLC patients who have failure in chemotherapy of tyrosine kinase inhibitor combined with platinum.
关键词
非小细胞肺癌/化疗/安罗替尼/多西他赛/耐药性/不良反应Key words
Non-small cell lung cancer/Anlotinib/Docetaxel/Chemotherapy/Drug resistance/Adverse reaction引用本文复制引用
出版年
2024
NETL
NSTL
万方数据